Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.
Christophe HEZODE,
PL Almasio,
S Bourgeois,
P Buggisch,
A Brown,
M Diago,
Y Horsmans,
L Serfaty,
F Szalay,
GB Gaeta,
R Planas,
M Schlag,
I Lonjon-Domanec,
E Omoruyi,
R DeMasi,
S Zeuzem,
Liver Int. 01/09/2017;37(9) : 1304-1313 10.1111/liv.13376 13/03/2017
Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis.
D Saadoun,
S Pol,
Y Ferfar,
L Alric,
Christophe HEZODE,
SN Si Ahmed,
L De Saint Martin,
C Comarmond,
AS Bouyer,
L Musset,
T Poynard,
M Resche-Rigon,
P Cacoub,
Gastroenterology. 01/07/2017;153(1) : 49-52.e5 10.1053/j.gastro.2017.03.006. 10/03/2017
Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
Christophe HEZODE,
Slim FOURATI,
Stephane CHEVALIEZ,
G Scoazec,
Alexandre SOULIER,
A Varaut,
M Francois,
Isaac RUIZ,
F Roudot-Thoraval,
A Mallat,
Jean-Michel PAWLOTSKY,
Clin Infect Dis. 01/06/2017;64(11) : 1615-1618 10.1093/cid/cix214. 24/07/2017
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
IM Jacobson,
E Lawitz,
PY Kwo,
Christophe HEZODE,
CY Peng,
AY Howe,
P Hwang,
J Wahl,
M Robertson,
E Barr,
BA Haber,
Gastroenterology. 01/05/2017;152(6) : 1372-1382.e2 10.1053/j.gastro.2017.01.050. 11/02/2017
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis
M Bourliere,
P Rabiega,
N Ganne-Carrie,
L Serfaty,
P Marcellin,
Y Barthe,
D Thabut,
D Guyader,
Christophe HEZODE,
M Picon,
X Causse,
V Leroy,
JP Bronowicki,
P Carrieri,
G Riachi,
I Rosa,
P Attali,
JM Molina,
Y Bacq,
A Tran,
JD Grange,
F Zoulim,
H Fontaine,
L Alric,
I Bertucci,
Magali BOUVIER-ALIAS,
F Carrat,
Lancet Gastroenterol Hepatol. 01/03/2017;2(3) : 177-188 10.1016/S2468-1253(16)30189-3 20/01/2017
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
S Pol,
M Bourliere,
S Lucier,
Christophe HEZODE,
C Dorival,
D Larrey,
JP Bronowicki,
VD Ledinghen,
F Zoulim,
A Tran,
S Metivier,
JP Zarski,
D Samuel,
D Guyader,
P Marcellin,
A Minello,
L Alric,
D Thabut,
O Chazouilleres,
G Riachi,
V Bourcier,
P Mathurin,
V Loustaud-Ratti,
L D'Alteroche,
I Fouchard-Hubert,
F Habersetzer,
X Causse,
C Geist,
I Rosa,
J Gournay,
E Saillard,
E Billaud,
V Petrov-Sanchez,
A Diallo,
H Fontaine,
F Carrat,
J Hepatol. 01/01/2017;66(1) : 39-47 10.1016/j.jhep.2016.08.021 10/09/2016
Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.
D Saadoun,
V Thibault,
SN Si Ahmed,
L Alric,
M Mallet,
C Guillaud,
H Izzedine,
A Plaisier,
H Fontaine,
M Costopoulos,
M Le Garff-Tavernier,
Christophe HEZODE,
S Pol,
L Musset,
T Poynard,
P Cacoub,
Ann Rheum Dis. 01/10/2016;75(10) : 1777-1782 10.1136/annrheumdis-2015-208339 13/11/2015
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France.
P Marcellin,
F Zoulim,
Christophe HEZODE,
X Causse,
B Roche,
R Truchi,
A Pauwels,
D Ouzan,
J Dumortier,
GP Pageaux,
M Bourliere,
G Riachi,
JP Zarski,
JF Cadranel,
V Tilliet,
C Stern,
P Petour,
O Libert,
SM Consoli,
D Larrey,
Dig Dis Sci. 01/10/2016;61(10) : 3072-3083 10.1007/s10620-015-4027-8. 28/01/2016
